0002001011-24-000028.txt : 20240229 0002001011-24-000028.hdr.sgml : 20240229 20240229185028 ACCESSION NUMBER: 0002001011-24-000028 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240227 FILED AS OF DATE: 20240229 DATE AS OF CHANGE: 20240229 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Espinoza Octavio CENTRAL INDEX KEY: 0001905248 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-33093 FILM NUMBER: 24706125 MAIL ADDRESS: STREET 1: C/O LIGAND PHARMACEUTICALS INC STREET 2: 3911 SORRENTO VALLEY BOULEVARD, STE 110 CITY: SAN DIEGO STATE: CA ZIP: 92121 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: LIGAND PHARMACEUTICALS INC CENTRAL INDEX KEY: 0000886163 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 770160744 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 3911 SORRENTO VALLEY BLVD STREET 2: SUITE 110 CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: 858-550-7500 MAIL ADDRESS: STREET 1: 3911 SORRENTO VALLEY BLVD STREET 2: SUITE 110 CITY: SAN DIEGO STATE: CA ZIP: 92121 4 1 edgardoc.xml PRIMARY DOCUMENT X0508 4 2024-02-27 0 0000886163 LIGAND PHARMACEUTICALS INC LGND 0001905248 Espinoza Octavio 3911 SORRENTO VALLEY, SUITE 110 SAN DIEGO CA 92121 0 1 0 0 Chief Financial Officer 0 Common Stock 2024-02-27 4 A 0 7208 0.0 A 28631 D Common Stock 2024-02-28 4 M 0 799 55.75 A 29430 D Common Stock 2024-02-28 4 M 0 140 57.22 A 29570 D Common Stock 2024-02-28 4 M 0 325 58.49 A 29895 D Common Stock 2024-02-28 4 S 0 140 88.46 D 29755 D Employee Stock Option (right to buy) 55.75 2024-02-28 4 M 0 799 0.0 D 2030-02-13 Common Stock 799 2869 D Employee Stock Option (right to buy) 57.22 2024-02-28 4 M 0 140 0.0 D 2030-10-01 Common Stock 140 7722 D Employee Stock Option (right to buy) 58.49 2024-02-28 4 M 0 325 0.0 D 2027-02-24 Common Stock 325 1607 D Employee Stock Option (right to buy) 89.2 2024-02-27 4 A 0 29272 0.0 A 2034-02-27 Common Stock 29272 29272 D Represents Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. The RSUs shall vest over three years, in three substantially equal annual installments on February 15, 2025; February 15, 2026; and February 15, 2027, subject to the Reporting Person's continued service to the Issuer through each such vesting date. As per the separation of OmniAb Inc. from the issuer, 2,039 stock options were vested and exercisable as of November 1, 2022, whereas 1,629 options vest in 16 substantially equal monthly installments beginning on November 13, 2022. As per the separation of OmniAb Inc. from the issuer, 4,096 stock options were vested and exercisable as of November 1, 2022, whereas 3,766 options vest in 23 substantially equal monthly installments beginning on December 1, 2022. The stock option is fully vested and exercisable. The Stock Option grant vests and is exercisable as to 12.5% of the underlying shares 6 months after the grant date, and in 42 substantially equal monthly installments thereafter. By: /s/ Andrew Reardon, Attorney-in-Fact For: Octavio Espinoza 2024-02-29